Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Pharmaceuticals, a specialty pharmaceutical company (Nasdaq: CTXR), announced presentations at two virtual investor conferences in January 2021. The H.C. Wainwright BioConnect Conference will feature CEO Myron Holubiak from January 11-14, with a presentation available on-demand starting January 11. The MoneyShow Accredited Investors Virtual Expo will feature Chairman Leonard Mazur on January 26. Key updates will include progress on i-MSC therapy for ARDS and Mino-Lok trials for CLABSIs. Citius is committed to advancing its product candidates in critical care.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has announced a series of webinars to discuss updates on the Phase 3 trial of Mino-Lok, an antibiotic lock solution designed for treating Central Line Associated Blood Stream Infections (CLABSIs). The trial is over halfway complete, with insights shared by experts from leading medical institutions. Key topics included the challenges of conducting the trial during COVID-19 and the benefits of Mino-Lok. CEO Myron Holubiak expressed optimism about meeting the unmet need for effective alternatives to central line replacements.

Citius Pharmaceuticals (CTXR) announced receiving guidance from the FDA regarding its Mino-Wrap, aimed at reducing infections in post-mastectomy patients. The FDA's feedback included suggestions for bio absorption studies and a large animal pharmacology study to support Mino-Wrap's development. Additionally, a 28-day toxicology study was deemed appropriate. This innovation, designed to enhance protection against infections during breast reconstruction surgeries, could address a significant issue, as infection rates for tissue expanders range from 2.5% to 24%. Citius emphasizes the importance of this solution amid current inadequate preventive measures.

Citius Pharmaceuticals (Nasdaq: CTXR) announced promising interim data from a proof-of-concept study on its proprietary induced mesenchymal stem cell (i-MSC) therapy for acute inflammatory respiratory conditions, such as COVID-19 related ARDS. The study showed significant improvements in oxygenation, reduced lung injury, and systemic shock in treated subjects compared to controls. Citius has partnered with Novellus Therapeutics for the development of i-MSCs and established a subsidiary, NoveCite, which has filed a Pre-IND with the FDA, indicating strong progress in their therapeutic approach.

Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in the Benzinga Global Small Cap Conference on December 8-9, 2020. Citius Chairman Leonard Mazur will present on December 8 at 11:30 am ET and conduct one-on-one meetings with investors. The company is advancing four proprietary product candidates, including Mino-Lok®, which is in Phase 3 trials, and Halo-Lido, expected to enter Phase 2b trials in early 2021. Recent developments include a positive interim analysis for Mino-Lok and an exclusive agreement with Novellus Therapeutics for a therapy related to COVID-19.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced results from a Boston Analytical study showing that Mino-Lok, a novel antiseptic solution, is more effective than standard EDTA/ethanol solutions in eradicating resistant Staphylococcal biofilms. The study revealed that Mino-Lok significantly reduced CFU/Disk counts in two strains of Staphylococcus aureus across various exposure times. This promising data supports the potential of Mino-Lok to transform the treatment of central venous catheter infections and underscores its significance in the ongoing Phase 3 pivotal trial.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced participation in the Virtual Fall Investor Summit from November 16-18, 2020. Chairman Leonard Mazur will present a corporate overview on November 16 at 1:00 p.m. ET and engage in one-on-one investor meetings. Updates on Mino-Wrap, focused on reducing surgical infection risks, and Mino-Lok®, aimed at treating catheter-related infections, will be discussed. The company recently licensed induced mesenchymal stem cells for potential COVID-19 treatment, indicating an expansion of its critical care drug portfolio.

Citius Pharmaceuticals, a late-stage specialty pharmaceutical company, announced its participation in the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020. CEO Myron Holubiak will present an update on the company’s product pipeline at 2:30 p.m. ET and conduct one-on-one investor meetings. This follows the release of their October 2020 Letter to Shareholders, detailing recent business and clinical developments. For more information, visit the corporate update.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced recent updates in its October 2020 Letter to Shareholders, highlighting significant developments in its drug pipeline. The company secured an exclusive license with Novellus Therapeutics for a therapy targeting acute respiratory distress syndrome (ARDS), a COVID-19 complication. It also received a positive report from the Drug Monitoring Committee for its Mino-Lok Phase 3 trial and submitted a pre-investigational new drug request for Mino-Wrap, with FDA guidance expected in November 2020. A Phase 2b trial for Halo-Lido is slated to start in Q1 2021.